Axon Enterprise (NASDAQ:AXON) Price Target Lowered to $702.00 at Barclays

Axon Enterprise (NASDAQ:AXON) had its price objective lowered by Barclays from $861.00 to $702.00 in a research note released on Thursday,Benzinga reports. Barclays currently has an overweight rating on the biotechnology company’s stock.

Several other research firms have also weighed in on AXON. The Goldman Sachs Group dropped their price objective on shares of Axon Enterprise from $940.00 to $800.00 and set a “buy” rating on the stock in a research note on Wednesday. JMP Securities reiterated a “market outperform” rating and set a $825.00 price objective on shares of Axon Enterprise in a report on Monday, September 29th. Zacks Research cut Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 2nd. Raymond James Financial reaffirmed an “outperform” rating and issued a $855.00 target price (up from $645.00) on shares of Axon Enterprise in a research report on Tuesday, August 5th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Axon Enterprise in a research note on Wednesday, October 8th. Fifteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, Axon Enterprise has a consensus rating of “Moderate Buy” and a consensus price target of $810.71.

Axon Enterprise Trading Up 2.6%

Shares of Axon Enterprise stock traded up $15.37 during trading on Thursday, hitting $602.51. The stock had a trading volume of 1,048,973 shares, compared to its average volume of 696,988. The stock has a 50 day simple moving average of $722.51 and a 200 day simple moving average of $734.37. The company has a market capitalization of $47.30 billion, a PE ratio of 148.77, a P/E/G ratio of 29.49 and a beta of 1.45. The company has a quick ratio of 2.71, a current ratio of 2.95 and a debt-to-equity ratio of 0.63. Axon Enterprise has a 1 year low of $469.24 and a 1 year high of $885.91.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $1.17 earnings per share for the quarter, missing the consensus estimate of $1.63 by ($0.46). The firm had revenue of $710.64 million for the quarter, compared to analysts’ expectations of $704.83 million. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The company’s revenue for the quarter was up 30.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.45 earnings per share. Axon Enterprise has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS. On average, research analysts expect that Axon Enterprise will post 5.8 EPS for the current fiscal year.

Insider Activity

In other Axon Enterprise news, President Joshua Isner sold 15,919 shares of the stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $746.26, for a total transaction of $11,879,712.94. Following the transaction, the president owned 238,379 shares in the company, valued at $177,892,712.54. This trade represents a 6.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Jeri Williams sold 100 shares of the business’s stock in a transaction on Thursday, September 11th. The stock was sold at an average price of $752.54, for a total transaction of $75,254.00. Following the transaction, the director directly owned 1,416 shares of the company’s stock, valued at approximately $1,065,596.64. This represents a 6.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 59,932 shares of company stock valued at $45,115,616. Insiders own 4.40% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of AXON. Vanguard Group Inc. raised its stake in Axon Enterprise by 4.2% during the 3rd quarter. Vanguard Group Inc. now owns 9,314,164 shares of the biotechnology company’s stock valued at $6,684,217,000 after purchasing an additional 376,904 shares during the last quarter. Geode Capital Management LLC grew its position in Axon Enterprise by 5.9% in the 2nd quarter. Geode Capital Management LLC now owns 2,072,186 shares of the biotechnology company’s stock worth $1,713,332,000 after purchasing an additional 115,349 shares during the last quarter. Alliancebernstein L.P. increased its holdings in shares of Axon Enterprise by 15.9% during the 1st quarter. Alliancebernstein L.P. now owns 1,284,935 shares of the biotechnology company’s stock worth $675,812,000 after purchasing an additional 175,890 shares during the period. Jennison Associates LLC raised its position in shares of Axon Enterprise by 53.8% during the third quarter. Jennison Associates LLC now owns 943,944 shares of the biotechnology company’s stock valued at $677,412,000 after buying an additional 330,213 shares during the last quarter. Finally, Westfield Capital Management Co. LP lifted its stake in shares of Axon Enterprise by 29.8% in the first quarter. Westfield Capital Management Co. LP now owns 927,801 shares of the biotechnology company’s stock valued at $487,977,000 after buying an additional 212,931 shares during the period. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.